JBP Plamon | Human Placenta Extract — Regulatory Notice for UK & EU Clinics
JBP Plamon, manufactured by Japan Bio Products, is a purified human placenta extract used in Korean and Japanese aesthetic and regenerative medicine — supplied as a mesotherapy injectable containing growth factors, amino acids, and other biologically active substances derived from human placental tissue.
Before this product is listed for sale, its UK and EU regulatory status needs to be independently verified. Unlike the synthetic HA, PDRN, and PLLA products elsewhere on this site — which carry clear CE marking under EU MDR and MHRA-recognised status in the UK — human placenta-derived biologics fall under a different, more complex regulatory framework in Western markets, covering biological source material, tissue and cell product regulations, and in some cases blood/plasma-adjacent safety rules. Several wholesale suppliers of JBP Plamon themselves note that its regulatory status for aesthetic use varies by market and may be considered off-label.
JBP Plamon is used in Korea and Japan to support tissue renewal, skin metabolism, and pigmentation reduction, with clinical research including a 2009 trial involving 108 women conducted by PharmaResearch at Seoul National University Hospital. However, this doesn’t establish its regulatory clearance for aesthetic use in the UK or EU, where placenta-derived products for cosmetic purposes are not commonly authorised.
JBP Plamon — human placenta extract used in Korean/Japanese regenerative aesthetic protocols. Not currently confirmed as CE-marked or MHRA-approved for aesthetic use in the UK or EU; regulatory review required before this product can be listed for sale on ProAestheticSupply.eu.
Buy JBP
Buy JBP
Buy JBP
Buy JBP
Buy JBP
Buy JBP
Buy JBP
Buy JBP
Buy JBP
Important Regulatory Information About JBP Plamon
Human placenta extract occupies a distinct regulatory category from the medical devices and cosmetic injectables stocked elsewhere on ProAestheticSupply.eu. Products derived from human biological tissue are typically subject to specific EU and UK regulations covering human tissue and cells (in the EU, this includes frameworks separate from the standard Medical Devices Regulation), and aesthetic use of placenta-derived injectables is not commonly authorised in either market.
Why hasn’t this product been given the same treatment as the rest of the catalogue?
Because I can’t verify CE marking or MHRA-recognised status for JBP Plamon’s use as a cosmetic/aesthetic injectable in the UK or EU — several of the wholesale sources selling it internationally acknowledge that its regulatory status for aesthetic use “varies by market” and “may be off-label.” Publishing sales copy that implies the same regulatory standing as your CE-marked HA fillers would misrepresent its actual status.
What should happen before this product is listed?
This is a decision for your regulatory or compliance contact, not something to resolve through product copy. If JBP Plamon (or similar human placenta-derived products) is confirmed appropriately licensed for supply and use in your target markets, I’m glad to write the full content set at that point, matching the format of your other 52 products.
Contact our customer support team for guidance on currently available, fully regulated alternatives within our skin boosters and mesotherapy ranges.